Alzheimer’s disease (AD) is a neurological disorder with variability in pathology and clinical progression. AD patients may differ in individual-level benefit from amyloid beta removal therapy.
Random forest models were applied to the EMERGE trial to create an individual-level treatment response (ITR) score which represents individual-level benefit of high-dose aducanumab relative to the placebo. This ITR score was used to test the existence of heterogeneity in treatment effect (HTE).
We found statistical evidence of HTE in the Clinical Dementia Rating–Sum of Boxes (CDR-SB;P = 0.034). The observed CDR-SB benefit was 0.79 points greater in the group with the top 25% of ITR score compared to the remaining 75% (P = 0.020). Of note, the highest treatment responders had lower hippocampal volume, higher plasma phosphorylated tau 181 and a shorter duration of clinical AD at baseline.
This ITR analysis provides a proof of concept for precision medicine in future AD research and drug development.
Emerging trials have shown a population-level benefit from amyloid beta (Aβ) removal in slowing cognitive decline in early Alzheimer’s disease (AD).
This work demonstrates significant heterogeneity of individual-level treatment effect of aducanumab in early AD.
The greatest clinical responders to Aβ removal therapy have a pattern of more severe neurodegenerative process.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Menglan Pang,
Paul M. Matthews,
Carl de Moor,
Changyu Shen | October 26, 2023